Variant Alpha-2-Macroglobulin Compositions for Targeted FAC Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for joint and spinal pain, particularly those related to inflammation and extracellular matrix degradation, are inadequate in differentiating between acute and chronic conditions, and there is a lack of effective methods to inhibit the formation of fibronectin aggrecan complex (FAC) which contributes to tissue damage.
Innovation Solution
Development of variant alpha-2-macroglobulin (A2M) polypeptides with enhanced protease inhibitory activity, specifically designed to inhibit serine proteases, threonine proteases, and other proteases involved in FAC formation, which are administered to treat inflammation, pain, and extracellular matrix degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional treatments are used for joint and spinal pain, then general anti-inflammatory effects are achieved, but the treatments cannot differentiate between acute and chronic conditions leading to inadequate targeted therapy
Solution Approach 1:
The patent introduces alpha-2-macroglobulin (A2M) as an intermediary substance that can detect and respond to different inflammatory states. A2M serves as a mediator between the diagnostic need (differentiating acute/chronic conditions) and therapeutic action (targeted protease inhibition), enabling a single agent to provide both diagnostic information and targeted treatment based on the specific condition present
2Object-affected harmful factors
If protease inhibitors are administered to inhibit FAC formation, then tissue degradation is reduced, but specific inhibition of fibronectin aggrecan complex formation is not achieved with conventional inhibitors
Solution Approach 1:
The patent modifies the A2M protein to have different functional properties in different contexts. The variant A2M polypeptide is engineered with specific alterations that enhance its ability to bind and inhibit proteases involved in FAC formation specifically, while maintaining its general protease inhibitory capabilities. This local quality enhancement allows selective targeting of harmful protease activity without affecting other physiological processes
3Quantity of substance
If broad-spectrum protease inhibition is achieved, then multiple protease activities are suppressed, but specificity for proteases involved in FAC formation is reduced
Solution Approach 1:
The patent employs parameter changes by modifying the amino acid sequence of A2M to alter its binding characteristics. Specific amino acid substitutions, deletions, or additions in the variant A2M polypeptide change its affinity and specificity for different proteases. This allows the protein to maintain broad protease inhibitory activity while enhancing its preference for binding proteases involved in fibronectin aggrecan complex formation, thus achieving both quantity and specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The variant A2M polypeptides effectively inhibit protease activity, reducing tissue degeneration, pain, and inflammation, and provide targeted treatment for joint and spinal conditions, including osteoarthritis and chronic wounds, with improved healing outcomes.
Implementation Method 1
The variant A2M polypeptides effectively inhibit protease activity, reducing tissue degeneration, pain, and inflammation
Data Source
AI summary
A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases.